Case report: An exceptional responder of low-dose continuous 5-FU in a patient with de-novo stage IV triple-negative breast cancer with liver and bone marrow failure
Continuous low-dose 5-FU was popularized as a therapy for pretreated metastatic breast cancer for the past few decades, spurred by the advent of the electronic infusion pump. Capecitabine, otherwise known by its trade name Xeloda, is a prodrug of 5-fluorouracil (5-FU), which is administered orally i...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2024-01-01
|
| Col·lecció: | Frontiers in Oncology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1305584/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|